Men and women who are 18+, with schizophrenia or schizoaffective
disorder, are invited to be involved in an adjunctive treatment study
that is underway in Melbourne. Hormones are known to play a role in the
expression of schizophrenia and related disorders. The Monash Alfred Psychiatry research centre is investigating whether a treatment that
targets hormones, when taken in combination with regular antipsychotic
medication, can better improve psychotic symptoms, mood and cognitive
functioning. Participants will be reimbursed for their time and travel
can be negotiated. See more: Link
10 Apr 2014
7 Apr 2014
Participants sought: Medication in smoking cessation
This MAPrc study will examine important safety aspects (such as agitation,
aggression and depression) of the drugs varenicline and bupropion
compared to placebo (“dummy pills” that do not contain any medicine) and
nicotine-replacement therapy (NRT or “the patch”) in smokers with or
without a history of being diagnosed with a psychiatric disorder. See
more: Link
Participants sought: Predicting optimized treatment in depression
MAPrc is investigating patient response versus non
patient response (i.e “controls” – defined as participants who do not
suffer from depression and are not on medication) to antidepressant
medications. A combination of brain measures (physical and mental) and
body functions will be analysed to determine patient response to
antidepressant medications using genetic, psychological and
physiological measures. Currently, there are no accurate predictors of
how patients will respond to antidepressant treatment. We would love to hear from you: Link
Subscribe to:
Posts (Atom)